Definitions and diagnosis of pulmonary hypertension
MM Hoeper, HJ Bogaard, R Condliffe, R Frantz… - Journal of the American …, 2013 - jacc.org
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure≥ 25 mm Hg
at rest, measured during right heart catheterization. There is still insufficient evidence to add …
at rest, measured during right heart catheterization. There is still insufficient evidence to add …
Diagnosis and assessment of pulmonary arterial hypertension
DB Badesch, HC Champion… - Journal of the American …, 2009 - jacc.org
The diagnosis and assessment of pulmonary arterial hypertension is a rapidly evolving area,
with changes occurring in the definition of the disease, screening and diagnostic techniques …
with changes occurring in the definition of the disease, screening and diagnostic techniques …
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
N Galie, A Manes, L Negro, M Palazzini… - European heart …, 2009 - academic.oup.com
Aims There is no cure for pulmonary arterial hypertension, but current approved treatment
options include prostanoids, endothelin-receptor antagonists, and phosphodiesterase type …
options include prostanoids, endothelin-receptor antagonists, and phosphodiesterase type …
[HTML][HTML] Inhaled iloprost for severe pulmonary hypertension
H Olschewski, G Simonneau, N Galiè… - … England Journal of …, 2002 - Mass Medical Soc
Background Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
M Humbert, RJ Barst, IM Robbins… - European …, 2004 - Eur Respiratory Soc
The efficacy and safety of combining bosentan, an orally active dual endothelin receptor
antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of …
antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of …
[HTML][HTML] Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia
RC Trembath, JR Thomson, RD Machado… - … England Journal of …, 2001 - Mass Medical Soc
Background Most patients with familial primary pulmonary hypertension have defects in the
gene for bone morphogenetic protein receptor II (BMPR2), a member of the transforming …
gene for bone morphogenetic protein receptor II (BMPR2), a member of the transforming …
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
Objectives: The purpose of this study was to assess the efficacy and safety of beraprost
sodium, an orally active prostacyclin analogue, in New York Heart Association (NYHA) …
sodium, an orally active prostacyclin analogue, in New York Heart Association (NYHA) …
The endothelin system in pulmonary arterial hypertension
N Galié, A Manes, A Branzi - Cardiovascular research, 2004 - academic.oup.com
Abstract Endothelin-1 (ET-1), a peptide produced primarily by vascular endothelial cells,
was discovered in 1980 and it was characterized as a powerful vasoconstrictor and mitogen …
was discovered in 1980 and it was characterized as a powerful vasoconstrictor and mitogen …
[PDF][PDF] BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension
RD Machado, MW Pauciulo, JR Thomson… - The American Journal of …, 2001 - cell.com
Primary pulmonary hypertension (PPH) is a potentially lethal disorder, because the
elevation of the pulmonary arterial pressure may result in right-heart failure. Histologically …
elevation of the pulmonary arterial pressure may result in right-heart failure. Histologically …
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension
MM Hoeper, JA Barberà, RN Channick… - Journal of the American …, 2009 - jacc.org
The 4th World Symposium on Pulmonary Hypertension was the first international meeting to
focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH …
focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH …